高防Ⅰ号预防急性高原病的研究

THE STUDY OF GAO FANG Ⅰ ON PREVENTING ACUTE HIGH ALTITUDE DISEASE

目的 :评估高防Ⅰ号的临床效果和对生理指标的影响 ,为推广应用提供科学依据。方法 :高原现场大人群对照研究。对象来自平原籍的健康男性 6650人 ,其中服用高防Ⅰ号的实验组 330 4人 ;不干预的对照组 334 6人。实验组进入高海拔地区 ( 4 80 0～ 5370m)前 1天或当天至进驻后 7～ 10d ,每日口服高防Ⅰ号 1～ 2粒。急性高原病 (AHAD)诊断与分型按第三次全国高原医学学术讨论会制定的标准判定。结果 :自身比较及与对照组比较有统计意义者为 :高防Ⅰ号组AHAD轻型和重型患病率各由 34 .79%和 2 .87%降为 8.87%和 0 .4 5% ;心搏出量 (SV)、每分钟心输出量 (CO)、右肺区域性血流量 (RSV)、血清含铜锌离子超氧化物岐化酶 (hSOD - 1)及血浆皮质醇 (C)增加 ;而脉率 (P)、动脉压 (MAP)、总外周阻力 (TPR)、血管紧张素Ⅱ (AngⅡ )、醛固酮(Ald)、谷丙转氨酶 (GPT)及磷酸肌酸激酶 (CPK)下降 ,微循环平均滞留时间 (TM)缩短。结论 :高防Ⅰ号预防AHAD作用肯定 ,效果显著 ;对AHAD发病机理中的血液动力学、内分泌激素。

Objective:For evaluating the clinical and physiological effects of 'Gao Fang Ⅰ' on preventing acute high altitude disease(AHAD). Methods:6 650 male and healthy subjects from sea level, including 3 304 subjects administrating 'Gao Fang Ⅰ' and 3 346 controls, were investigated. The subjects took 'Gao Fang Ⅰ' 1～2 tablets/day the days before and after entering high altitude(4 800～5 370 m) for 7～10 days. Diagnosis and classification of AHAD were determined according to the standard made in the 3rd National High Altitude Medicine Symposium.Results:The morbidity rate of mild AHAD and severe AHAD decreased to 8.87% and 0.45% respectively after taking 'Gao Fang Ⅰ', as compared to the control (34.79% and 2.87% respectively).The physiological parameters showed that stroke volume (SV),cardiac output (CO), right situation volume(RSV), superoxide dismutase (SOD) and cortisol (C) were increased, while pulse rate (P), mean arterial pressure(MAP),total peripheral resistance(TPR),angiotensin Ⅱ(Ang Ⅱ),aldosterone(Ald),GPT,CPK and mean time of microcirculation(TM) were decreased. Conclusion:'Gao Fang Ⅰ' had positive and remarkable effects on preventing AHAD. It may have good intervention on the pathogenesis of AHAD including hemodynamics, endocrine hormone, metabolism of free radicals and enzyme etc.